BH_NonClinical_Pharmacy_Car-T

Barts Health NHS Trust, located in London, has completed a procurement process for the provision of CAR-T therapy products, a cutting-edge personalised immunotherapy treatment to fight cancer. The contract is under the industry category of medical equipment, pharmaceuticals, and pharmacy services, and it was directly awarded to Bristol Myers Squibb due to their unique capabilities in this area. The contract, which has a start date of 8th December 2025, will have an initial duration of five years with an option to extend for an additional five years.

There are no minimum order commitments, and prices are capped at those approved by NICE/NHS England. This tender presents substantial business growth opportunities, especially for enterprises specialising in medical innovations and pharmaceuticals. Large suppliers with capacity to provide sophisticated medical treatments like CAR-T therapy may find this contract with the public healthcare sector advantageous in establishing long-term partnerships.

Given the exclusive supplier arrangements owing to the intellectual property considerations, businesses possessing similar exclusive capabilities can leverage such procurement opportunities to expand their footprint within the UK's healthcare market.